OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 01, 2022
New and emerging biotherapeutic molecules drive the need for innovative solutions to meet cold-chain requirements.
December 02, 2021
Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
October 22, 2021
Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.
EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.
October 02, 2021
The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
September 09, 2021
Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.
September 02, 2021
Establishing analytical workflows for complex biopharmaceutical molecules can help predict their risk of degradation.
August 06, 2021
Syngene International appoints two US-based executives to senior level positions.
August 02, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.